Neuronal nicotinic receptor ligands and their use
OwnerMarleen Verlinden, Michael Meyer +3inventors
InventorsMarleen Verlinden, Michael Meyer, Michael Decker, James Sullivan, William Bunnelle
Life of this patent
Estimating the term…
Abstract
The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect tolerability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositions and products.
Claims19
A method of identifying a neuronal nicotinic receptor ligand, comprising the steps of:
- (a) assessing a compound for selective binding to α4β2 neuronal nicotinic receptor subtype;
- (b) assessing a compound for ability to stimulate ion channel flux into a cell expressing α4β2, α3β4, or α3β2 neuronal nicotinic receptor subtypes;
- and
- (c) identifying a compound selected for α4β2 neuronal nicotinic receptor subtype that demonstrates weak ability to stimulate ion channel flux into the cell expressing α4β2, α3β4, or α3β2 neuronal nicotinic receptor subtypes that is not a neuronal nicotinic receptor antagonist.
A method for treating a mammal having a condition or disorder where modulation of nicotinic acetylcholine receptor activity is of therapeutic benefit, the method comprising administering to a subject having or subsceptible to said condition or disorder with a therapeutically effective amount of a compound demonstrating selective binding for α4β2 neuronal nicotinic receptor subtype and weak agonist activity in cells expressing α4β2, α3β4, or α3β2 neuronal nicotinic receptor subtypes, except neuronal nicotinic receptor antagonists.
A method of using ABT-089 human clinical data to obtain regulatory authorization, comprising the steps of:
- (a) providing ABT-089 human clinical data to a regulatory agency having authority to assess or regulate, or both, pharmaceutical compounds or products, or both;
- and
- (b) obtaining approval to manufacture or market a desired pharmaceutical compound from the regulatory agency.
Dependencies are inferred from the claim text.